44 results on '"Kater, Arnon P."'
Search Results
2. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia
- Author
-
Tonino, Sanne H, Mulkens, Chantal E, van Laar, Jacoline, Derks, Ingrid AM, Suo, Guangli, Boer, Fransien Croon-de, van Oers, Marinus HJ, Eldering, Eric, Wang, Jean Y, and Kater, Arnon P
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Hematology ,Rare Diseases ,Lymphoma ,Clinical Research ,Cancer ,Development of treatments and therapeutic interventions ,2.1 Biological and endogenous factors ,5.1 Pharmaceuticals ,Aetiology ,Antigens ,Surface ,Antineoplastic Agents ,Apoptosis ,Apoptosis Regulatory Proteins ,BH3 Interacting Domain Death Agonist Protein ,Biomarkers ,Cell Cycle ,Cell Cycle Checkpoints ,Cell Line ,Tumor ,Cell Proliferation ,Cisplatin ,Cyclin-Dependent Kinase Inhibitor p21 ,DNA-Binding Proteins ,Drug Resistance ,Neoplasm ,Gene Expression Regulation ,Neoplastic ,Gene Knockdown Techniques ,Humans ,Leukemia ,Lymphocytic ,Chronic ,B-Cell ,Lymph Nodes ,Nuclear Proteins ,Platinum ,Proto-Oncogene Proteins ,Proto-Oncogene Proteins c-abl ,Tumor Protein p73 ,Tumor Suppressor Protein p53 ,Tumor Suppressor Proteins ,Chronic lymphocytic leukemia ,drug resistance ,p53 ,TAp73 ,CDDP ,Clinical Sciences ,Immunology ,Cardiovascular medicine and haematology - Abstract
In chronic lymphocytic leukemia (CLL), strategies to overcome drug resistance due to p53 dysfunction are highly needed. Platinum-based compounds such as cisplatinum (CDDP) are active in fludarabine-refractory CLL through a largely unknown mechanism. We analyzed the mechanism of action of CDDP in the context of p53 dysfunctionality. In vitro treatment with CDDP did not induce death in quiescent CLL cells, but did induce apoptosis in CD40-ligand (and CpG) stimulated and proliferating cells, irrespective of p53 function. In the p53 dysfunctional prolymphocytic cell-line MEC1, CDDP treatment resulted in apoptosis, cell cycle arrest and ABL1-dependent expression of TAp73, CDKN1A, PUMA and BID. TAp73 RNA-interference decreased sensitivity to CDDP. Finally, both in vitro stimulated CLL cells and lymph node (LN) derived CLL cells showed increased TAp73 expression in comparison with quiescent peripheral blood derived cells. Activity of CDDP may therefore be mediated by TAp73, especially in the context of activation such as occurs in the LN microenvironment.
- Published
- 2015
3. Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care.
- Author
-
Anderson, Mary Ann, Walewska, Renata, Hackett, Fidelma, Kater, Arnon P., Montegaard, Josie, O'Brien, Susan, Seymour, John F., Smith, Matthew, Stilgenbauer, Stephan, Whitechurch, Ashley, and Brown, Jennifer R.
- Subjects
THERAPEUTIC use of antineoplastic agents ,CHRONIC lymphocytic leukemia ,PROTEINS ,RISK assessment ,HEMATOLOGIC malignancies ,TUMOR lysis syndrome ,IMMUNOGLOBULINS ,TREATMENT effectiveness ,PATIENT care ,CANCER patients ,CYTOREDUCTIVE surgery ,CASE studies ,INDIVIDUALIZED medicine ,HEALTH care teams - Abstract
Simple Summary: Venetoclax has proven a viable option for treatment of chronic lymphocytic leukemia (CLL), with high response rates and a generally manageable safety profile. Management considerations associated with venetoclax initiation include the risk of tumor lysis syndrome (TLS), which requires close attention and prompt management. Administration of venetoclax in a safe manner through a slow ramping up of the dose over a 5-week period, along with proper assessment, preparation, and initiation, are essential and have been successful in reducing the risk of TLS in patients with CLL. This review summarizes hypothetical patient case scenarios and emphasizes the importance of a collaborative team effort, with perspectives from highly respected clinicians in the field offering invaluable insight for optimal patient care and treatment strategies. Venetoclax, a highly selective, oral B-cell lymphoma 2 inhibitor, provides a robust targeted-therapy option for the treatment of chronic lymphocytic leukemia (CLL), including patients with high-risk del(17p)/mutated-TP53 and immunoglobulin heavy variable region unmutated CLL and those refractory to chemoimmunotherapy across all age groups. Due to the potent pro-apoptotic effect of venetoclax, treatment initiation carries a risk of tumor lysis syndrome (TLS). Prompt and appropriate management is needed to limit clinical TLS, which may entail serious adverse events and death. Venetoclax ramp-up involves gradual, stepwise increases in daily venetoclax dosing from 20 mg to 400 mg (target dose) over 5 weeks; adherence to on-label scheduling provides a tumor debulking phase, reducing the risk of TLS. The key components of safe venetoclax therapy involve assessment (radiographic evaluation and baseline blood chemistry), preparation (adequate hydration), and initiation (blood chemistry monitoring). In addition to summarizing the evidence for venetoclax's efficacy and safety, this review uses hypothetical patient scenarios based on risk level for TLS (high, medium, low) to share the authors' clinical experience with venetoclax initiation and present global approaches utilized in various treatment settings. These hypothetical scenarios highlight the importance of a multidisciplinary approach and shared decision-making, outlining best practices for venetoclax initiation and overall optimal treatment strategies in patients with CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia.
- Author
-
Haggenburg, Sabine, Garcia Garrido, Hannah M., Kant, Iris M. J., Van der Straaten, Hanneke M., De Boer, Fransien, Kersting, Sabina, Issa, Djamila, Te Raa, Doreen, Visser, Hein P. J., Kater, Arnon P., Goorhuis, Abraham, and De Heer, Koen
- Subjects
CHRONIC lymphocytic leukemia ,IMMUNE response ,PNEUMOCOCCAL vaccines ,POLYSACCHARIDES ,LYMPHOCYTE count - Abstract
Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23). Because both CLL as well as immunosuppressive treatment have been identified as major determinants of immunogenicity, we aimed to assess the vaccination schedule in untreated and treated CLL patients. We quantified pneumococcal IgG concentrations against five serotypes shared across both vaccines, and against four serotypes unique to PPSV23, before and eight weeks after vaccination. In this retrospective cohort study, we included 143 CLL patients, either treated (n = 38) or naive to treatment (n = 105). While antibody concentrations increased significantly after vaccination, the overall serologic response was low (10.5%), defined as a ≥4-fold antibody increase against ≥70% of the measured serotypes, and significantly influenced by treatment status and prior lymphocyte number. The serologic protection rate, defined as an antibody concentration of ≥1.3 µg/mL for ≥70% of serotypes, was 13% in untreated and 3% in treated CLL patients. Future research should focus on vaccine regimens with a higher immunogenic potential, such as multi-dose schedules with higher-valent T cell dependent conjugated vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia
- Author
-
Zhang, Weizhou, Kater, Arnon P., Widhopf, George F., Chuang, Han-Yu, Enzler, Thomas, James, Danelle F., Poustovoitov, Maxim, Tseng, Ping-Hui, Janz, Siegfried, Hoh, Carl, Herschman, Harvey, Karin, Michael, and Kipps, Thomas J.
- Published
- 2010
6. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.
- Author
-
van der Straten, Lina, Levin, Mark-David, Dinnessen, Manette A. W., Visser, Otto, Posthuma, Eduardus F. M., Doorduijn, Jeanette K., Langerak, Anton W., Kater, Arnon P., and Dinmohamed, Avinash G.
- Subjects
SECONDARY primary cancer ,CHRONIC lymphocytic leukemia ,CHRONIC leukemia - Abstract
The longevity of patients with chronic lymphocytic leukemia (CLL) has improved progressively over the past decades, making it essential to understand long-term health outcomes, such as second primary malignancies (SPMs). Therefore, this nationwide, population-based study assessed the risk of SPM development in CLL patients diagnosed during 1989-2019 in the Netherlands compared to the expected number of malignancies in an age-, sex-, and period-matched group from the general Dutch population. In 24,815 CLL patients followed for 162,698.49 person-years, 4369 SPMs were diagnosed with a standardized incidence ratio (SIR) of 1.63 (95% confidence interval [CI] 1.59–1.68). This elevated risk was observed for solid (SIR, 1.67; 95% CI, 1.65–1.75) and hematological SPMs (SIR 1.42; 95% CI, 1.24–1.62). The highest risk for SPMs was noted beyond five years post-diagnosis (SIR, 1.70; 95% CI, 1.62–1.77), for male individuals (SIR, 1.70; 95% CI, 1.64–1.77), and patients aged 18–69 years (SIR, 1.92; 95% CI, 1.79–2.05). The risk of SPMs was higher in CLL patients who received anti-neoplastic therapy (SIR, 2.12; 95% CI, 1.96–2.28), as compared with those who did not (SIR, 1.58; 95% CI, 1.53–1.63). Routine surveillance activities and tailored interventions to counteract the increased morbidity and excess mortality associated with SPMs are essential for improving long-term outcomes in CLL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
- Author
-
Raa, Doreen G. Te, van der Straten, Lina, van Gelder, Michel, Kersting, Sabina, Levin, Mark-David, Mous, Rogier, van der Straaten, Hanneke M., Nijziel, Marten R., van der Spek, Ellen, Posthuma, Eduardus F. M, Visser, Hein P.J, van der Klift, Marjolein, de Heer, Koen, Bellido, Mar, Doorduijn, Jeanette K., Bruns, Anke H.W, Raijmakers, Reinier A. P, and Kater, Arnon P.
- Subjects
CHRONIC lymphocytic leukemia ,DIAGNOSIS - Abstract
Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.
- Author
-
Davies, Andrew, Kater, Arnon P, Sharman, Jeff P, Stilgenbauer, Stephan, Vitolo, Umberto, Klein, Christian, Parreira, Joana, and Salles, Gilles
- Subjects
CHRONIC lymphocytic leukemia ,ANTINEOPLASTIC agents ,MONOCLONAL antibodies ,NON-Hodgkin's lymphoma - Abstract
The type II anti-CD20 antibody obinutuzumab has structural and mechanistic features that distinguish it from the first anti-CD20 antibody, rituximab, which have translated into improved efficacy in phase III trials in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). These gains have been shown through improvements in, and/or increased durability of, tumor response, and increases in progression-free survival in patients with CLL or follicular lymphoma (FL). Ongoing research is focusing on the use of biomarkers and the development of chemotherapy-free regimens involving obinutuzumab. phase II trials of such treatment regimens have shown promise for CLL, FL and mantle cell lymphoma, while phase III trials have highlighted obinutuzumab as the antibody partner of choice for novel agents in first-line CLL treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
- Author
-
Kater, Arnon P, Levin, Mark-David, Dubois, Julie, Kersting, Sabina, Enggaard, Lisbeth, Veldhuis, Gerrit J, Mous, Rogier, Mellink, Clemens H M, van der Kevie-Kersemaekers, Anne-Marie F, Dobber, Johan A, Poulsen, Christian B, Frederiksen, Henrik, Janssens, Ann, Schjødt, Ida, Dompeling, Ellen C, Ranti, Juha, Brieghel, Christian, Mattsson, Mattias, Bellido, Mar, and Tran, Hoa T T
- Subjects
- *
CHRONIC lymphocytic leukemia , *RESEARCH , *CLINICAL trials , *HETEROCYCLIC compounds , *CARCINOGENESIS , *PURINES , *RESEARCH methodology , *ANTINEOPLASTIC agents , *EVALUATION research , *PIPERIDINE , *COMPARATIVE studies , *RANDOMIZED controlled trials , *SULFONAMIDES - Abstract
Background: Targeted time-limited treatment options are needed for patients with relapsed or refractory chronic lymphocytic leukaemia. The aim of this study was to investigate the efficacy of minimal residual disease (MRD)-guided, time-limited ibrutinib plus venetoclax treatment in this patient group.Methods: HOVON141/VISION was an open-label, randomised, phase 2 trial conducted in 47 hospitals in Belgium, Denmark, Finland, the Netherlands, Norway, and Sweden. Eligible participants were aged 18 years or older with previously treated chronic lymphocytic leukaemia with or without TP53 aberrations; had not been exposed to Bruton tyrosine-kinase inhibitors or BCL2 inhibitors; had a creatinine clearance rate of 30 mL/min or more; and required treatment according to International Workshop on Chronic Lymphocytic Leukemia 2018 criteria. Participants with undetectable MRD (<10-4; less than one chronic lymphocytic leukaemia cell per 10 000 leukocytes) in peripheral blood and bone marrow after 15 28-day cycles of oral ibrutinib (420 mg once daily) plus oral venetoclax (weekly ramp-up 20 mg, 50 mg, 100 mg, 200 mg, up to 400 mg once daily) were randomly assigned (1:2) to ibrutinib maintenance or treatment cessation. Patients who were MRD positive continued to receive ibrutinib monotherapy. Patients who became MRD (>10-2) during observation reinitiated treatment with ibrutinib plus venetoclax. The primary endpoint was progression-free survival at 12 months after random assignment in the treatment cessation group. Progression-free survival was analysed in the intention-to-treat population. All patients who received at least one dose of study drug were included in the safety assessment. The study is registered at ClinicalTrials.gov, NCT03226301, and is active but not recruiting.Findings: Between July 12, 2017, and Jan 21, 2019, 230 patients were enrolled, 225 of whom were eligible. 188 (84%) of 225 completed treatment with ibrutinib plus venetoclax and were tested for MRD at cycle 15. After cycle 15, 78 (35%) patients had undetectable MRD and 72 (32%) were randomly assigned to a treatment group (24 to ibrutinib maintenance and 48 to treatment cessation). The remaining 153 patients were not randomly assigned and continued with ibrutinib monotherapy. Median follow-up of 208 patients still alive and not lost to follow-up at data cutoff on June 22, 2021, was 34·4 months (IQR 30·6-37·9). Progression-free survival after 12 months in the treatment cessation group was 98% (95% CI 89-100). Infections (in 130 [58%] of 225 patients), neutropenia (in 91 [40%] patients), and gastrointestinal adverse events (in 53 [24%] patients) were the most frequently reported; no new safety signals were detected. Serious adverse events were reported in 46 (40%) of 116 patients who were not randomly assigned and who continued ibrutinib maintenance after cycle 15, eight (33%) of 24 patients in the ibrutinib maintenance group, and four (8%) of 48 patients in the treatment cessation group. One patient who was not randomly assigned had a fatal adverse event (bleeding) deemed possibly related to ibrutinib.Interpretation: These data point to a favourable benefit-risk profile of MRD-guided, time-limited treatment with ibrutinib plus venetoclax for patients with relapsed or refractory chronic lymphocytic leukaemia, suggesting that MRD-guided cessation and reinitiation is feasible in this patient population.Funding: AbbVie and Janssen. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018.
- Author
-
van der Straten, Lina, Maas, Carolien C. H. M., Levin, Mark-David, Visser, Otto, Posthuma, Eduardus F. M., Doorduijn, Jeanette K., Langerak, Anton W., Kater, Arnon P., and Dinmohamed, Avinash G.
- Subjects
CHRONIC lymphocytic leukemia ,LIFE expectancy ,CHRONIC leukemia - Abstract
However, this would only potentially influence estimates for patients diagnosed during the 1990s since the age-standardized incidence rate of CLL in the Netherlands remained comparatively steady as of the early 2000s, and the life expectancy of CLL patients continued to increase thereafter [[2]]. As the LEL has not been assessed for CLL patients, our nationwide, population-based study complements and extends the study of Kajüter and colleagues by estimating the life expectancy of CLL patients. We read with interest the article by Kajüter and colleagues about the relative survival of 2,327 patients with chronic lymphocytic leukemia (CLL) diagnosed from 1993 to 2016 in Münster, Germany [[1]]. We thus encourage monitoring the progress in the population level survival of CLL patients since excess mortality persists in modern times, even for CLL patients surviving up to ten years post-diagnosis [[14]]. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
11. Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.
- Author
-
van der Straten, Lina, Hengeveld, Paul J., Kater, Arnon P., Langerak, Anton W., and Levin, Mark-David
- Subjects
CHRONIC lymphocytic leukemia ,B cell receptors ,KARYOTYPES - Abstract
The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Over the past decades, several cytogenetic, immunogenetic and molecular features have emerged that identify patients suffering from CLL with high-risk molecular features. These biomarkers can clearly aid prognostication, but may also be capable of predicting the efficacy of various treatment strategies in subgroups of patients. In this narrative review, we discuss treatment approaches to CLL with high-risk molecular features. Specifically, we review and provide a comprehensive overview of clinical trials evaluating the efficacy of chemotherapy, chemoimmunotherapy and novel agent-based treatments in CLL patients with TP53 aberrations, deletion of the long arm of chromosome 11, complex karyotype, unmutated IGHV, B cell receptor stereotypy, and mutations in NOTCH1 or BIRC3. Furthermore, we discuss future pharmaceutical and immunotherapeutic perspectives for CLL with high-risk molecular features, focusing on agents currently under investigation in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Human CXCR5+PD‐1+ CD8 T cells in healthy individuals and patients with hematologic malignancies.
- Author
-
Hofland, Tom, Martens, Anne W.J., Bruggen, Jaco A.C., Boer, Renate, Schetters, Sjoerd, Remmerswaal, Ester B.M., Bemelman, Frederike J., Levin, Mark‐David, Bins, Adriaan D., Eldering, Eric, Kater, Arnon P., and Tonino, Sanne H.
- Subjects
T cells ,CHRONIC lymphocytic leukemia ,FLUDARABINE ,PROGRAMMED cell death 1 receptors - Abstract
Immune checkpoint blockade (ICB) has revolutionized cancer therapy, but varying response rates illustrate the need for biomarkers of response. Studies in mice have identified a subset of CD8 T cells that is essential for response to PD‐1 ICB. These CD8 T cells co‐express CXCR5, PD‐1 and Tcf1, and provide effector T cells upon PD‐1 ICB. It is unknown whether similar T cells play a role in PD‐1 ICB in humans. We studied human peripheral blood and lymph nodes (LNs) for the frequency, phenotype, and functionality of CXCR5+PD‐1+ CD8 T cells. We find that CXCR5+PD‐1+ CD8 T cells are memory‐like cells, express Tcf1, and lack expression of effector molecules. CXCR5+PD‐1+ CD8 T cells produce cytokines upon stimulation, but have limited proliferative capacity. We studied patients with hematologic malignancies with varying response rates to PD‐1 ICB. Specifically in chronic lymphocytic leukemia, in which PD‐1 ICB does not induce clinical responses, CXCR5+PD‐1+ CD8 T cells show loss of the memory phenotype and increased effector differentiation. In conclusion, we identified CXCR5+PD‐1+ CD8 T cells in human peripheral blood and LN, which could play a similar role during PD‐1 ICB. Future studies should analyze CXCR5+PD‐1+ CD8 T cells during PD‐1 ICB and their importance for therapeutic response. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer.
- Author
-
Leeksma, Alexander C., Derks, Ingrid A. M., Kasem, M. Haidar, Kilic, Emine, de Klein, Annelies, Jager, Martine J., van de Loosdrecht, Arjan A., Jansen, Joop H., Navrkalova, Veronika, Faber, Laura M., Zaborsky, Nadja, Egle, Alexander, Zenz, Thorsten, Pospisilova, Sarka, Abdel-Wahab, Omar, Kater, Arnon P., and Eldering, Eric
- Subjects
DNA damage ,CHRONIC lymphocytic leukemia ,MESSENGER RNA ,POSTHARVEST diseases ,LYMPHOCYTOSIS ,CHRONIC leukemia ,CELL lines - Abstract
Recurrent mutations in splicing factor 3B subunit 1 (SF3B1) have been identified in several malignancies and are associated with an increased expression of 3' cryptic transcripts as a result of alternative branchpoint recognition. A large fraction of cryptic transcripts associated with SF3B1 mutations is expected to be sensitive for RNA degradation via nonsense-mediated mRNA decay (NMD). Several studies indicated alterations in various signaling pathways in SF3B1-mutated cells, including an impaired DNA damage response (DDR) in chronic lymphocytic leukemia (CLL). In this study, we investigated isogenic cell lines and treatment naïve primary CLL samples without any TP53 and/or ATM defect, and found no significant effects of SF3B1 mutations on the ATM/p53 response, phosphorylation of H2AX and sensitivity to fludarabine. Cryptic transcripts associated with SF3B1 mutation status were observed at relatively low levels compared to the canonical transcripts and were validated as target for mRNA degradation via NMD. Expression of cryptic transcripts increased after NMD inhibition. In conclusion, our results confirm involvement of NMD in the biological effects of SF3B1 mutations. Further studies may elucidate whether SF3B1 -mutant patients could benefit from NMD modulatory agents. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
- Author
-
Svanberg, Rebecka, Ostrowski, Sisse Rye, Nasserinejad, Kazem, Kersting, Sabina, Dobber, Johan A., Mattson, Mattias, Tran, Hoa T. T., Levin, Mark-David, Mous, Rogier, Kater, Arnon P., and Niemann, Carsten U.
- Subjects
CHRONIC lymphocytic leukemia ,HEMOSTASIS ,THROMBIN receptors ,ADENOSINE diphosphate ,ARACHIDONIC acid ,ALOPECIA areata ,CHRONIC leukemia - Abstract
Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL) at baseline, during ibrutinib monotherapy, and during venetoclax and ibrutinib combination therapy or venetoclax monotherapy. Primary hemostasis, assessed by Multiplate using adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin receptor agonist peptide (TRAP-6), was impaired in all CLL patients at baseline, remained unchanged upon ibrutinib monotherapy, and improved significantly following venetoclax added to ibrutinib or as monotherapy. Secondary hemostasis assessed by thromboelastography (TEG) was normal and unchanged throughout treatment. The frequency of clinical bleeding events was the highest during ibrutinib monotherapy, in line with the demonstrated improved primary hemostasis upon addition of venetoclax, thus pointing toward a treatment option for CLL patients with increased bleeding risk. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
- Author
-
Haselager, Marco V., Kater, Arnon P., and Eldering, Eric
- Subjects
CHRONIC lymphocytic leukemia ,B cell receptors ,T helper cells ,ANTIGEN receptors ,TOLL-like receptors - Abstract
Chronic lymphocytic leukemia (CLL) cells cycle between lymphoid tissue sites where they actively proliferate, and the peripheral blood (PB) where they become quiescent. Strong evidence exists for a crucial role of B cell receptor (BCR) triggering, either by (self-)antigen or by receptor auto-engagement in the lymph node (LN) to drive CLL proliferation and provide adhesion. The clinical success of Bruton's tyrosine kinase (BTK) inhibitors is widely accepted to be based on blockade of the BCR signal. Additional signals in the LN that support CLL survival derive from surrounding cells, such as CD40L-presenting T helper cells, myeloid and stromal cells. It is not quite clear if and to what extent these non-BCR signals contribute to proliferation in situ. In vitro BCR triggering, in contrast, leads to low-level activation and does not result in cell division. Various combinations of non-BCR signals delivered via co-stimulatory receptors, Toll-like receptors (TLRs), and/or soluble cytokines are applied, leading to comparatively modest and short-lived CLL proliferation in vitro. Thus, an unresolved gap exists between the condition in the patient as we now understand it and applicable knowledge that can be harnessed in the laboratory for future therapeutic applications. Even in this era of targeted drugs, CLL remains largely incurable with frequent relapses and emergence of resistance. Therefore, we require better insight into all aspects of CLL growth and potential rewiring of signaling pathways. We aim here to provide an overview of in vivo versus in vitro signals involved in CLL proliferation, point out areas of missing knowledge and suggest future directions for research. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Survival continues to increase in chronic lymphocytic leukaemia: a population‐based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.
- Author
-
Straten, Lina, Levin, Mark‐David, Visser, Otto, Posthuma, Eduardus F. M., Doorduijn, Jeanette K., Kater, Arnon P., and Dinmohamed, Avinash G.
- Subjects
LEUKEMIA ,GENERAL practitioners ,CHRONIC lymphocytic leukemia - Abstract
Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016 Keywords: chronic lymphocytic leukaemia; survival; cancer epidemiology; population-based; registry EN chronic lymphocytic leukaemia survival cancer epidemiology population-based registry 574 577 4 04/30/20 20200501 NES 200501 Chronic lymphocytic leukaemia (CLL) is the most frequently diagnosed and prevalent form of leukaemia among adults in Western countries (Brenner I et al. i , [2]; Kristinsson I et al. i , [6]; Van den Broek I et al. i , [9]). Relative survival (RS) is the overall survival (OS) in the patient cohort divided by the expected OS of an equivalent group from the general population, matched to the patient group by age, sex, and period (Dickman & Adami, [3]). Furthermore, the incidence of CLL might be overestimated, because most patients diagnosed with Rai stage 0 or I before 2008 can be reclassified into monoclonal B-cell leukaemia according to the most recent diagnostic criteria (Hallek I et al. i , [5]). [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
17. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population‐based study in the Netherlands.
- Author
-
Straten, Lina, Levin, Mark‐David, Visser, Otto, Blijlevens, Nicole M.A., Cornelissen, Jan J., Doorduijn, Jeanette K., Kater, Arnon P., and Dinmohamed, Avinash G.
- Subjects
LEUKEMIA ,CHRONIC lymphocytic leukemia ,CLINICAL trial registries - Abstract
At present, in the Netherlands, the application in daily practice of ibrutinib in patients with chronic lymphocytic leukaemia (CLL) is, as yet, restricted to CLL patients with del(17p) or a I TP53 i mutation across all treatment lines, and in particular to patient subsets with previously treated CLL (Kersting I et al. i , [5]). All CLL patients who initiated treatment with commercially available ibrutinib between 2015 and 2016 in the Netherlands were identified and queried via the Nationwide Registry of Hospital Discharges (i.e. inpatient and outpatient discharges) and the nationwide Netherlands Cancer Registry. Of note, AEs occurred more abundantly in patients with anaemia, as compared to patients without anaemia (57% vs. 38%; I P i = 0-021). Survival outcomes among ibrutinib-treated patients with chronic lymphocytic leukaemia according to the line of therapy (i.e. first-line therapy versus and subsequent lines of therapy). [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
18. Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
- Author
-
Deng, Rong, Gibiansky, Leonid, Lu, Tong, Li, Xiaobin, Lu, Dan, Li, Chunze, Girish, Sandhya, Wang, Jue, Boyer, Michelle, Shankar, Noopur, Humphrey, Kathryn, Freise, Kevin J., Salem, Ahmed Hamed, Seymour, John F., Kater, Arnon P., and Miles, Dale
- Subjects
CHRONIC lymphocytic leukemia ,LYMPHOCYTIC leukemia ,DOSE-response relationship in biochemistry ,LOGISTIC regression analysis ,RITUXIMAB - Abstract
Exposure–response relationships from a phase 1b (M13-365) and phase 3 (MURANO) study were investigated to assess benefit/risk of venetoclax 400 mg daily plus rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dose intensities were summarized by tertiles of predicted venetoclax steady-state average concentrations based on nominal venetoclax dose (C
meanSS,nominal ) for tolerability; exposure–safety analyses used logistic regression. Exposure–progression-free survival (PFS) relationships were assessed using MURANO data, with CmeanSS,nominal as a grouping factor. Covariates were demographics, geographic region, study, baseline disease characteristics, ECOG performance status, responsiveness to prior therapy, and chromosomal abnormalities. There was no significant effect of covariates on grade ≥3 neutropenia/infection or PFS, and no relationship between venetoclax exposure and these endpoints, or venetoclax or rituximab dose intensity. These results support the recommended venetoclax 400 mg daily dose in combination with rituximab in patients with R/R CLL or small lymphocytic leukemia. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
19. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
- Author
-
Deng, Rong, Gibiansky, Leonid, Lu, Tong, Agarwal, Priya, Ding, Hao, Li, Xiaobin, Kshirsagar, Smita, Lu, Dan, Li, Chunze, Girish, Sandhya, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Freise, Kevin J., Salem, Ahmed Hamed, Seymour, John F., Kater, Arnon P., and Miles, Dale
- Subjects
RITUXIMAB ,CHRONIC lymphocytic leukemia ,PHARMACOKINETICS ,CYTOCHROME P-450 ,VENETOCLAX - Abstract
Background: Venetoclax is a selective B-cell lymphoma-2 (BCL-2) inhibitor approved for use as monotherapy or with rituximab in patients with chronic lymphocytic leukemia (CLL). The objectives of the current analysis of observed data from adult patients randomized to venetoclax-rituximab in the phase III MURANO study were to characterize venetoclax pharmacokinetics (PKs) using a Bayesian approach, evaluate whether a previously developed population PK model for venetoclax can describe the PKs of venetoclax when administered with rituximab, and to determine post hoc estimates of PK parameters for the exposure-response analysis.Methods: Parameter estimates and uncertainty estimated by a population PK model were used as priors. Additional covariate effects (CLL risk status, geographic region, and 17p deletion [del(17p)] status) were added to the model. The updated model was used to describe venetoclax PKs after repeated dosing in combination with rituximab, and to determine post hoc estimates of PK parameters for exposure-response analysis.Results: The PK analysis included 600 quantifiable venetoclax PK samples from 182 patients in the MURANO study. Model evaluation using standard diagnostic plots, visual predictive checks, and normalized prediction distribution error plots indicated no model deficiencies. There was no significant relationship between venetoclax apparent clearance (CL/F) and bodyweight, age, sex, mild and moderate hepatic and renal impairment, or coadministration of weak cytochrome P450 3A inhibitors. The chromosomal abnormality del(17p) and CLL risk status had no apparent effect on the PKs of venetoclax. A minimal increase in venetoclax CL/F (approximately 7%) was observed after coadministration with rituximab. CL/F was 30% lower in patients from Central and Eastern Europe (n = 60) or Asia (n = 4) compared with other regions (95% confidence interval [CI] 21-39%). Apparent central volume of distribution was 30% lower (95% CI 22-38%) in females (n = 56) compared with males (n = 126). No clinically significant impact of region or sex was observed on key safety and efficacy outcomes.Conclusions: The Bayesian model successfully characterized venetoclax PKs over time and confirmed key covariates affecting PKs in the MURANO study. The model was deemed appropriate for further use in simulations and for generating individual patient PK parameters for subsequent exposure-response evaluation. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
- Author
-
van der Straten, Lina, Dinmohamed, Avinash G., Westerweel, Peter E., Langerak, Anton W., Riedl, Jurgen, Doorduijn, Jeanette K., Kater, Arnon P., and Levin, Mark-David
- Subjects
RITUXIMAB ,CANCER chemotherapy ,CHRONIC lymphocytic leukemia ,LYSIS ,ANTIBODY-dependent cell cytotoxicity - Abstract
The article offers information on a study regarding rituximab (R) addition to chemotherapy in patients with chronic lymphocytic leukemia (CLL). It mentions that the effectiveness of +R in the first-line treatment of CLL patients is not restricted to selected patients in RCTs. It states that the loss of CD20 and changes in cell surface markers CD55 and CD59, leading to diminished antibody-dependent cellular cytotoxicity and attenuated complement dependent cell lysis.
- Published
- 2018
- Full Text
- View/download PDF
21. Ibrutinib: searching for a partner drug.
- Author
-
Kater, Arnon P and Brown, Jennifer R
- Subjects
- *
CHRONIC lymphocytic leukemia , *CHRONIC leukemia - Published
- 2019
- Full Text
- View/download PDF
22. The 8th Young Investigators' Meeting on Chronic Lymphocytic Leukemia.
- Author
-
Kater, Arnon P., Lanasa, Mark C., Wesselmann, Johanna, and Fischer, Kirsten
- Subjects
- *
CHRONIC lymphocytic leukemia , *CONFERENCES & conventions - Abstract
The article discusses the 8th annual Young Investigators' Meeting (YIM) on chronic lymphocytic leukemia (CLL) which was held during the 15th International Workshop on CLL (iwCLL) in Cologne, Germany on September 8, 2013. Among the participants were keynote speaker Peter Hillmen, 15th iwCLL host Michael Hallek, and "Leukemia & Lymphoma" periodical editor in chief Aaron Polliack.
- Published
- 2015
- Full Text
- View/download PDF
23. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.
- Author
-
Raa, G. Doreen, Malčiková, Jitka, Mraz, Marek, Trbusek, Martin, Le Garff‐Tavernier, Magali, Merle‐Béral, Hélène, Greil, Rudolf, Merkel, Olaf, Pospíšilová, Sarka, Lin, Ke, Pettitt, Andrew R., Stankovic, Tatjana, Oers, Marinus H., Eldering, Eric, Stilgenbauer, Stephan, Zenz, Thorsten, and Kater, Arnon P.
- Subjects
IMMUNOASSAY ,REGULATOR of G-protein-signaling proteins ,REGULATOR genes ,CHRONIC lymphocytic leukemia ,GENETIC mutation ,PATIENTS - Abstract
The article presents a study on the use of RNA-based assays in assessing TP53, a regulator of the DNA-damage response pathway, functionality in patients with chronic lymphocytic leukemia (CLL). It discusses the aims of the study, the characterization of CLL, and mutational analysis of TP53 and ATM regulators.
- Published
- 2014
- Full Text
- View/download PDF
24. Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.
- Author
-
te Raa, G. Doreen, Malcikova, Jitka, Pospisilova, Sarka, Trbusek, Martin, Mraz, Mark, Garff-Tavernier, Maria Le, Merle-Béral, Hélène, Lin, Ke, Pettitt, Andrew R., Merkel, Olaf, Stankovic, Tatjana, van Oers, Marinus H., Eldering, Eric, Stilgenbauer, Stephan, Zenz, Thorsten, and Kater, Arnon P.
- Subjects
P53 antioncogene ,DNA damage ,ATAXIA telangiectasia mutated protein ,CHRONIC lymphocytic leukemia treatment ,CHRONIC lymphocytic leukemia ,FLUORESCENCE in situ hybridization ,DELETION mutation ,PROGNOSIS - Abstract
The ATM-p53 DNA damage response pathway plays a crucial role in chemoresistance in chronic lymphocytic leukemia, as indicated by the adverse prognostic impact of deletions of 17p (locus of TP53) and 11q (locus of ATM) detected by fluorescence in situ hybridization (FISH) analysis. In addition to deletions, mutations in these respective genes are also associated with chemoresistance, and add to the prognostic information provided by FISH. In order to explore the possibility that dysfunction of the ATM-p53 pathway might also result from mechanisms other than ATM/ TP53 deletion/mutation, assays have been developed that probe the functional integrity of the ATM-p53 pathway. Currently, four different p53 function assays have been developed that are based on the measurement of p53 and p53-dependent genes at the RNA (real-time polymerase chain reaction [RT-PCR] p21; RT-PCR miR34a; reverse transcription-multiplex ligation-dependent probe amplification assay [RT-MLPA] p21, bax, puma and CD95) or protein (fluorescence activated cell sorting [FACS]p53-p21) level in untreated cells or following irradiation or drug treatment. Here we provide an overview of these assays based on the available literature. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia.
- Author
-
Tonino, Sanne H., van de Berg, Pablo J., Yong, Si La, Ten Berge, Ineke J., Kersten, Marie José, van Lier, René A. W., van Oers, Marinus H., and Kater, Arnon P.
- Subjects
T cells ,LYMPHOMAS ,CHRONIC lymphocytic leukemia ,CYTOMEGALOVIRUSES ,APOPTOSIS ,B cell lymphoma - Abstract
In patients with chronic lymphocytic leukemia (CLL), numbers of CD8 + CD45RA +/− CD27− effector T cells are expanded. We investigated whether this expansion is also present in other B cell malignancies and the possible mechanism underlying these changes. Whereas an increase in total CD4+and CD8+ T cell numbers was found only in CLL, numbers of CD4+ and CD8+ effector T cells were significantly increased in both CLL and indolent lymphoma, but not aggressive lymphoma and myeloma. Interestingly, PD-1 expression was decreased on effector T cells and inversely correlated with effector T cell numbers, suggesting a functional role for PD-1 in regulating T cell homeostasis. In vitro experiments revealed impaired up-regulation of PD-1 upon T cell activation in the presence of malignant but also healthy B cells. Our data suggest that in CLL and indolent lymphoma, the malignant B cells affect PD-1 expression on effector T cells, resulting in an expansion of these subsets. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
26. Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis.
- Author
-
te Raa, G. Doreen, Fischer, Kathelijn, Verweij, Wim, van Houte, Arend J., Kater, Arnon P., and Biesma, Douwe H.
- Subjects
LYMPHOPROLIFERATIVE disorders ,LYMPHOCYTES ,B cells ,NEUTROPENIA ,CHRONIC lymphocytic leukemia ,PRIMARY care ,DISEASES - Abstract
Background: Detection of absolute and relative lymphocytosis in otherwise asymptomatic elderly patients is very common in the primary care setting and frequently results in referral for screening of lymphoproliferative disorders. Since many B-cell chronic lymphoproliferative disorders (B-CLPD) are indeed asymptomatic at diagnosis in most patients with lymphocytosis, no sign of such a disorder is usually detected. Currently, specific guidelines for screening of patients with lymphocytosis are lacking. We investigated the practicability and clinical value of a single colour CD19 count performed by a primary care laboratory in order to improve the diagnostic follow-up of patients with lymphocytosis in a primary care laboratory. Methods: The capability of detecting monoclonal B-cell lymphocytosis and B-CLPD by CD19, was first confirmed in patient samples with known B-CLPD. Next, in a previously defined geographic area, a CD19 count was performed on all samples for patients aged ≥40 years with relative or absolute lymphocytosis but without neutropenia. Clinical follow-up, with a median of 4 years, was performed using both a survey among the requesting general practitioners and by analysis of the records of the referral hospitals within the borders of the defined area. Results: A total of 520 cases with asymptomatic lymphocytosis were identified. In all cases, the CD19 count was performed; 207 (40%) showed increased values and 313 (60%) showed normal values. An increase in CD19 proved highly sensitive for detection of B-CLPD (98%, 95% CI; 94%-100%) with a high positive predictive value (57%, 95% CI; 50%-63%). The area under curve, the receiver-operating characteristic curve of the CD19 count (0.93, 95% CI; 0.91-0.96), was significantly higher compared to the absolute lymphocyte count (0.86, 95% CI; 0.83-0.89), especially in patients with moderate lymphocytosis. Conclusions: This study indicates that the CD19 count, performed by a primary care laboratory, is feasible and a promising tool for initial screening of lymphocytosis to discriminate B-CLPD from benign causes of lymphocytosis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
27. Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.
- Author
-
Delgado, Raquel, Kielbassa, Karoline, ter Burg, Johanna, Klein, Christian, Trumpfheller, Christine, de Heer, Koen, Kater, Arnon P., and Eldering, Eric
- Subjects
CHRONIC lymphocytic leukemia ,RITUXIMAB ,CYTOKINES ,FLOW cytometry ,IMMUNE checkpoint proteins ,WESTERN immunoblotting ,APOPTOSIS ,MONOCLONAL antibodies ,CELL receptors ,GENE expression ,TREATMENT effectiveness ,ENZYME-linked immunosorbent assay ,TUMOR necrosis factors ,IMMUNOTHERAPY - Abstract
Simple Summary: Previous observations have shown that CD40 activation of CLL cells via coculture with CD40L-expressing fibroblasts increases sensitivity to cell death by CD20 mAbs rituximab and obinutuzumab. We studied the activity of the fully human-agonistic CD40 mAb selicrelumab in primary CLL cells in relation to cell activation, induced pro-survival profile and sensitization for cell death by aCD20 mAbs. We found that the pro-survival effect of selicrelumab is minimal, while cell death by combined selicrelumab plus anti-CD20 antibody treatment is maintained. Thus, further investigation of applying selicrelumab combined with anti-CD20 mAbs in a therapeutic setting might be considered. Objectives: Chronic lymphocytic leukemia (CLL) is a common form of leukemia with a heterogeneous clinical course that remains incurable due to the development of therapy resistance. In lymph node proliferation centers, signals from the microenvironment such as CD40 ligation through interaction with follicular T helper cells shield CLL cells from apoptosis. Previous observations have shown that, despite CD40-induced changes in apoptotic mediators resulting in cell survival, CD40 activation also increases sensitivity to cell death by CD20 mAbs rituximab and obinutuzumab. To further investigate these observations, we here studied the activity of the fully human agonistic CD40 mAb selicrelumab in primary CLL cells in relation to cell activation, induced pro-survival profile, and sensitization for cell death by aCD20 mAbs, in vitro. Methods: CLL cells from peripheral blood were isolated by the Ficoll density method. The expression of activation markers and cytokine production following CD40 stimulation was quantified by flow cytometry and ELISA. The anti-apoptotic profile of CLL induced by stimulation was evaluated by the expression of BCL-2 proteins with Western blot, and resistance to venetoclax with flow cytometry. Cell death induced by the combination of selicrelumab and aCD20 mAbs was quantified by flow cytometry. Results: CLL cells treated with selicrelumab upregulated co-stimulatory molecules such as CD86, TNF-α and death receptor CD95/Fas. In contrast to the CD40 ligand-transfected NIH3T3 cells, induction of resistance to venetoclax by selicrelumab was very moderate. Importantly, selicrelumab stimulation positively sensitized CLL cells to CD20-induced cell death, comparable to CD40 ligand-transfected NIH3T3 cells. Conclusions: Taken together, these novel insights into selicrelumab-stimulatory effects in CLL may be considered for developing new therapeutic strategies, particularly in combination with obinutuzumab. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. miR in CLL: more than mere markers of prognosis?
- Author
-
Kater, Arnon P. and Eldering, Eric
- Subjects
- *
MICRORNA , *CHRONIC lymphocytic leukemia , *B cells , *CELL receptors , *TUMOR suppressor genes - Abstract
The authors discusses a study by M. Mraz and colleagues that was published within the issue of the journal that microRNA-150 (miR-150) is the most abundantly expressed miR in chronic lymphocytic leukemia (CLL). They outline the researchers' view on the effect of the miR-150 on the threshold for B-cell receptor (BCR) signaling. They also note the development of miR-based therapeutics that either upregulate the expression of tumor-suppressive miRs or downregulate the function of oncogenic miRs.
- Published
- 2014
- Full Text
- View/download PDF
29. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
- Author
-
Kater, Arnon P., Levin, Mark-David, and Niemann, Carsten U.
- Subjects
- *
CHRONIC lymphocytic leukemia , *CHRONIC leukemia , *ADULT respiratory distress syndrome - Published
- 2019
- Full Text
- View/download PDF
30. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma.
- Author
-
van Bruggen, Jaco A. C., Martens, Anne W. J., Tonino, Sanne H., and Kater, Arnon P.
- Subjects
THERAPEUTIC use of antineoplastic agents ,THERAPEUTIC use of immunoglobulins ,B cell lymphoma ,CELL receptors ,CHRONIC lymphocytic leukemia ,GENETIC engineering ,IMMUNOTHERAPY ,LYMPHOMAS ,T cells ,TREATMENT effectiveness ,IMMUNE checkpoint inhibitors ,EVALUATION ,THERAPEUTICS - Abstract
Simple Summary: The activity of novel therapies that utilize patient's own T-cells to induce remission of B-cell non-Hodgkin lymphoma (B-NHL), including chronic lymphocytic leukemia (CLL), is still suboptimal. In this review, we summarize the clinical efficacy of T-cell-based therapies in B-NHL and provide a biologic rationale for the observed (lack of) responses. We describe and compare the acquired T-cell dysfunctions that occur in the different subtypes of B-NHL. Furthermore, we discuss new insights that could enhance the efficacy of T-cell-based therapies for B-NHL and CLL. The next frontier towards a cure for B-cell non-Hodgkin lymphomas (B-NHL) is autologous cellular immunotherapy such as immune checkpoint blockade (ICB), bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cells. While highly successful in various solid malignancies and in aggressive B-cell leukemia, this clinical success is often not matched in B-NHL. T-cell subset skewing, exhaustion, expansion of regulatory T-cell subsets, or other yet to be defined mechanisms may underlie the lack of efficacy of these treatment modalities. In this review, a systematic overview of results from clinical trials is given and is accompanied by reported data on T-cell dysfunction. From these results, we distill the underlying pathways that might be responsible for the observed differences in clinical responses towards autologous T-cell-based cellular immunotherapy modalities between diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). By integration of the clinical and biological findings, we postulate strategies that might enhance the efficacy of autologous-based cellular immunotherapy for the treatment of B-NHL. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. Highlights of the 5th Young Investigators' Meeting on chronic lymphocytic leukemia.
- Author
-
Fischer, Kirsten, Shanafelt, Tait, and Kater, Arnon P.
- Subjects
CHRONIC lymphocytic leukemia ,PROTO-oncogenes ,LYMPHOCYTIC leukemia ,PROGNOSIS ,CAREER development ,MEETINGS ,CONFERENCES & conventions - Abstract
Information regarding the 5th Young Investigators' Meeting (YIM) on chronic lymphocyte leukemia (CLL), held on September 3, 2010 is presented. Topics include the prognostic importance of the expression of the lymphoid proto-oncogene TCL1 in T-cell prolymphocytic leukemia (T-PLL), the role of vimentin overexpression in patients with CLL and poor prognosis, and career development. The meeting featured various CLL researchers including Marc Lanasa, Matthew Davids, and Jasmin Bahlo.
- Published
- 2011
- Full Text
- View/download PDF
32. Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.
- Author
-
Hofland, Tom, Eldering, Eric, Kater, Arnon P., and Tonino, Sanne H.
- Abstract
Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction. CLL cells affect the phenotype and function of the entire spectrum of innate and adaptive immune cells, including monocytes, T cells, and natural killer (NK) cells, leading to a tumor-supportive environment and reduced immunosurveillance. Novel immunotherapies like immune checkpoint blockade, bi- and tri-specific antibodies, and chimeric antigen receptor (CAR) T cells use the patients' immune system to induce therapeutic responses. Although these novel immunotherapies showed impressive results in several B cell lymphomas, responses in CLL were often disappointing. The strong immunomodulatory effect of CLL is believed to play a pivotal role in the low response rates to these immunotherapeutic strategies. In this review, we summarize how CLL influences the function of non-malignant lymphocytes, with a special focus on T and NK cells, two important cellular mediators for immunotherapy. Secondly, we provide a short overview of the activity of several immunotherapeutics in CLL, and discuss how novel strategies may overcome the disappointing response rates in CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Highlights of the 7th Young Investigators' Meeting on Chronic Lymphocytic Leukemia.
- Author
-
Lanasa, Mark C., Kater, Arnon P., Shanafelt, Tait, and Fischer, Kirsten
- Subjects
- *
CHRONIC lymphocytic leukemia , *VESICLES (Cytology) , *P53 protein , *SOMATIC mutation , *CONFERENCES & conventions - Abstract
Information on several papers discussed at the 7th Young Investigators' Meeting on chronic lymphocytic leukemia (CLL) held in Königswinter, Germany on September 14, 2012 is presented. Topics include the prognostic impact of somatic mutations in TP53 protein, the role of extracellular vesicles in CLL survival, and CLL cell signaling and novel therapeutic agents. Neil Kay, Daniel Mertens and Jennifer Brown were among those who presented these papers at the meeting.
- Published
- 2013
- Full Text
- View/download PDF
34. Highlights of the 6th Young Investigators' Meeting on chronic lymphocytic leukemia.
- Author
-
Kater, Arnon P., Shanafelt, Tait, Fischer, Kirsten, and Wierda, William
- Subjects
- *
CHRONIC lymphocytic leukemia , *MONOCLONAL antibodies , *DRUG resistance , *CHROMOSOME abnormalities , *GENOMICS , *CONFERENCES & conventions - Abstract
Information about topics discussed at the 6th annual Young Investigators' Meeting (YIM) on chronic lymphocytic leukemia (CLL) held in Houston, Texas in 2011 is presented. Topics include genomic aberrations, novel mechanisms of monoclonal antibody resistance, and the putative influence of race on CLL biology. Speakers of the said event include Thorsten Zenz, Neil Kay, and Kanti Rai.
- Published
- 2012
- Full Text
- View/download PDF
35. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
- Author
-
de Rooij, Martin F. M., Kuil, Annemieke, Kater, Arnon P., Kersten, Marie José, Pals, Steven T., and Spaargaren, Marcel
- Subjects
- *
B cells , *MANTLE cell lymphoma , *CHRONIC lymphocytic leukemia - Abstract
A letter to the editor is presented regarding a rationale for combination therapy of ibrutinib and idelalisib in B-cell receptor (BCR)-controlled adhesion in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) .
- Published
- 2015
- Full Text
- View/download PDF
36. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
- Author
-
Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., and Kersting, Sabina S.
- Subjects
- *
CHRONIC lymphocytic leukemia , *IMMUNOGLOBULIN heavy chains , *PROTEOMICS - Abstract
• The prognostic ability of IGHV mutational status and sex was validated in this cohort. • The markers sCD23, SPINT1, and LY9 have possible prognostic ability for EFS in CLL patients. • Patients with these marker levels above the median had a shorter EFS than those with marker levels below the median. • Unmutated IGHV patients with an sCD23 or sCD27 level above the median had the lowest EFS. Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of known (proteomic) markers measured pretreatment and to search for new proteomic markers that might be related to treatment response in CLL. To this end, baseline serum samples of 51 CLL patients treated with chemo-immunotherapy were analyzed for 360 proteomic markers, using Olink technology. Median event-free survival (EFS) was 23 months (range: 1.25–60.9). Patients with high levels of sCD23 (>11.27, p = 0.026), sCD27 (>11.03, p = 0.04), SPINT1 (>1.6, p = 0.001), and LY9 (>8.22, p = 0.0003) had a shorter EFS than those with marker levels below the median. The effect of sCD23 on EFS differed between immunoglobulin heavy chain variable gene-mutated and unmutated patients, with the shortest EFS for unmutated CLL patients with sCD23 levels above the median. Taken together, our results validate the prognostic impact of sCD23 and highlight SPINT1 and LY9 as possible promising markers for treatment response in CLL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
- Author
-
van der Valk, Marc, Zaaijer, Hans L., Kater, Arnon P., and Schinkel, Janke
- Subjects
- *
HEPATITIS E virus , *CELL transplantation , *RIBAVIRIN , *CHRONIC lymphocytic leukemia , *PATIENTS ,SOFOSBUVIR - Abstract
The article presents case study of a 60-year-old patient with chronic lymphatic leukemia (CLL) who received an allogenic stem cell transplantation in 2006. It mentions that he was diagnosed with an acute hepatitis E virus (HEV) genotype 3 infection for which ribavirin (RBV) was started. It reveals Sofosbuvir shows antiviral activity in a patient with chronic HEV infection.
- Published
- 2017
- Full Text
- View/download PDF
38. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
- Author
-
Hofland, Tom, de Weerdt, Iris, ter Burg, Hanneke, de Boer, Renate, Tannheimer, Stacey, Tonino, Sanne H., Kater, Arnon P., and Eldering, Eric
- Subjects
- *
FLUDARABINE , *LYMPHOCYTES , *CHRONIC lymphocytic leukemia , *T cells , *KINASE inhibitors , *CELL proliferation - Abstract
Despite the emergence of small molecule inhibitors, current treatment strategies for chronic lymphocytic leukemia (CLL) are not curative, and the search for new therapeutic modalities continues. Prosurvival signaling derived from the microenvironment is often mediated via JAK signaling. However, whether JAK inhibitors are useful in CLL therapy has not been studied extensively. JAK inhibitors are valuable therapeutic agents in myelofibrosis and show promising results in graft-versus-host-disease. However, JAK inhibition is associated with an increased infection risk, presumably because of the effect on other immune cells, a feature shared with other kinase inhibitors used for CLL treatment, such as the BTK inhibitor ibrutinib and the PI3Kδ inhibitor idelalisib. We compared functional effects of the JAK1/2 inhibitors momelotinib and ruxolitinib, the BTK inhibitors ibrutinib and tirabrutinib, and PI3Kd inhibitor idelalisib on malignant CLL cells but also on healthy human T, B, and NK lymphocytes. We found several interesting differences among the inhibitors, apart from expected and well-known effects. Momelotinib but not ruxolitinib blocked cytokine-induced proliferation of CLL cells. Momelotinib also reduced BCR signaling, in contrast to ruxolitinib, indicating that these JAK inhibitors in fact have a distinct target spectrum. In contrast to tirabrutinib, ibrutinib had inhibitory effects on T cell activation, probably because of ITK inhibition. Remarkably, both BTK inhibitors stimulated IFN-γ production in a mixed lymphocyte reaction. Collectively, our results demonstrate that kinase inhibitors directed at identical targets may have differential effects on lymphocyte function. Their unique profile could be strategically employed to balance desired versus unwanted lymphocyte inhibition. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. Higher-order connections between stereotyped subsets
- Author
-
Andrea Patriarca, Marco Montillo, Niki Stavroyianni, Claudia Haferlach, Lesley-Ann Sutton, Livio Trentin, Franco Fais, Raphael Sandaltzopoulos, Arnon P. Kater, Anton W. Langerak, Marine Armand, Davide Rossi, Diane F. Jelinek, Davide Bagnara, Lydia Scarfò, Andreas Agathangelidis, Krzysztof Giannopoulos, Eugen Tausch, Andrey Sudarikov, Silvio Veronese, Salem H. Alshemmari, B V Biderman, Zadie Davis, Chrysoula Belessi, Lisa Bonello, Achilles Anagnostopoulos, Gerlinde Mitterbauer-Hohendanner, David Oscier, Sofia Kossida, Lone Bredo Pedersen, Paolo Ghia, Csaba Bödör, Christian Brieghel, Andrea Visentin, Véronique Giudicelli, Matthias Ritgen, Panagiotis Panagiotidis, Panagiotis Baliakas, Stephan Stilgenbauer, Ellen J van Gastel, Renee C. Tschumper, Christiane Pott, Frederic Davi, Katerina Gemenetzi, Valentina Guido, Elias Campo, Gianluca Gaidano, Irina Panovska, Sabine Jeromin, Karla Plevová, Kostas Stamatopoulos, Kamila Brázdilová, Maria Karypidou, Alba Navarro, Christof W. Schneider, Theodoros Moysiadis, Larry Mansouri, Darko Antic, Cristina Tresoldi, Constance Baer, Šárka Pospíšilová, Maria Roumelioti, Katrina Vanura, Xiao-Jie Yan, Hana Skuhrová Francová, Richard Rosenquist, Blanca Espinet, Paola Francia di Celle, Monica Facco, Paul Costeas, Michael Hallek, Carsten Utoft Niemann, Teodora Karan-Djurasevic, Manja Meggendorfer, Kirsten Fischer, Aleksandar Dimovski, Letizia Foroni, Marie-Paule Lefranc, Mark Catherwood, Anne de Septenville, Anastasia Chatzidimitriou, Sarah Lawless, Nicholas Chiorazzi, Agathangelidis, Andrea, Chatzidimitriou, Anastasia, Gemenetzi, Katerina, Giudicelli, Veronique, Karypidou, Maria, Plevova, Karla, Davis, Zadie A, Yan, Xiao-Jie, Jeromin, Sabine, Schneider, Christof, Pedersen, Lone Bredo, Tschumper, Renee, Sutton, Lesley A, Baliakas, Panagioti, Scarfò, Lydia, van Gastel, Ellen J, Armand, Marine, Tausch, Eugen, Biderman, Bella, Baer, Constance, Bagnara, Davide, Navarro, Alba, de Septenville, Anne, Guido, Valentina, Mitterbauer-Hohendanner, Gerlinde, Dimovski, Aleksandar, Brieghel, Christian, Lawless, Sarah, Meggendorfer, Manja, Stranska, Kamila, Ritgen, Matthia, Facco, Monica, Tresoldi, Cristina, Visentin, Andrea, Patriarca, Andrea, Catherwood, Mark, Bonello, Lisa, Sudarikov, Andrey, Vanura, Katrina, Roumelioti, Maria, Skuhrova Francova, Hana, Moysiadis, Theodoro, Veronese, Silvio M, Giannopoulos, Krzysztof, Mansouri, Larry, Karan-Djurasevic, Teodora, Sandaltzopoulos, Raphael, Bödör, Csaba, Fais, Franco, Kater, Arnon P, Panovska-Stavridis, Irina, Rossi, Davide, Alshemmari, Salem, Panagiotidis, Panagioti, Costeas, Paul A, Espinet, Blanca, Antic, Darko, Foroni, Letizia, Montillo, Marco, Trentin, Livio, Stavroyianni, Niki, Gaidano, Gianluca, Francia di Celle, Paola, Niemann, Carsten Utoft, Campo, Elía, Anagnostopoulos, Achille, Pott, Christiane, Fischer, Kirsten, Hallek, Michael, Oscier, David Graham, Stilgenbauer, Stephan, Haferlach, Claudia, Jelinek, Diane F, Chiorazzi, Nichola, Pospisilova, Sarka, Lefranc, Marie-Paule, Kossida, Sofia, Langerak, Anton W, Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, Experimental Immunology, Clinical Haematology, AII - Cancer immunology, CCA - Cancer biology and immunology, and Immunology
- Subjects
Chronic lymphocytic leukemia ,Immunology ,B-cell receptor ,Immunoglobulin Variable Region ,Disease ,Computational biology ,Biology ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Gene Frequency ,hemic and lymphatic diseases ,Immunoglobulin ,medicine ,Humans ,Chronic ,030304 developmental biology ,Gene Rearrangement ,0303 health sciences ,Leukemia ,Lymphoid Neoplasia ,Repertoire ,B-Cell ,breakpoint cluster region ,Cell Biology ,Hematology ,Gene rearrangement ,Somatic Hypermutation ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Lymphocytic ,Stereotypy (non-human) ,Immunoglobulin Heavy Chains ,Somatic Hypermutation, Immunoglobulin ,030220 oncology & carcinogenesis ,IGHV@ - Abstract
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed “satellites,” were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL. Key Points: • In a series of 29 856 CLL patients, the incidence of BcR stereotypy peaked at 41%. • Higher-order relations exist between stereotyped subsets, particularly for those from U-CLL, for which satellite subsets were identified.
- Published
- 2021
40. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
- Author
-
Thijssen, Rachel, ter Burg, Johanna, Garrick, Brett, van Bochove, Gregor G. W., Brown, Jennifer R., Fernandes, Stacey M., Rodríguez, María Solé, Michot, Jean-Marie, Hallek, Michael, Eichhorst, Barbara, Reinhardt, Hans Christian, Bendell, Johanna, Derks, Ingrid A. M., van Kampen, Roel J. W., Hege, Kristen, Kersten, Marie José, Trowe, Torsten, Filvaroff, Ellen H., Eldering, Eric, and Kater, Arnon P.
- Subjects
- *
B cell receptors , *CHRONIC lymphocytic leukemia , *RAPAMYCIN , *LYMPH nodes , *KINASE inhibitors - Abstract
Inhibition of B-cell receptor (BCR) signaling pathways in chronic lymphocytic leukemia (CLL) provides significant clinical benefit to patients, mainly by blocking adhesion of CLL cells in the lymph node microenvironment. The currently applied inhibitors ibrutinib and idelalisib have limited capacity however to induce cell death as monotherapy and are unlikely to eradicate the disease. Acquired resistance to therapy in CLL is often caused by mutations in the response network being targeted, both for DNA damage or BCR signaling pathways. Thus, drugs with dual targeting capacity could offer improved therapeutic value. Here, the potency of CC-115, a novel inhibitor of mammalian target of rapamycin kinase (TORK) and DNA-dependent protein kinase (DNA-PK),was evaluated in primary CLL cells in vitro and in CLL patients. Combined TORK and DNA-PK inhibition in vitro resulted in caspase-dependent cell killing irrespective of p53, ATM, NOTCH1, or SF3B1 status. Proliferation induced by CD40+ interleukin-21 stimulation was completely blocked by CC-115, and CD40-mediated resistance to fludarabine and venetoclax could be reverted by CC-115. BCR-mediated signaling was inhibited by CC-115 and also in CLL samples obtained from patients with acquired resistance to idelalisib treatment. Clinical efficacy of CC-115 was demonstrated in 8 patients with relapsed/refractory CLL/small lymphocytic lymphoma harboring ATM deletions/mutations; all but 1 patient had a decrease in lymphadenopathy, resulting in 1 IWCLL partial response (PR) and 3 PRs with lymphocytosis. In conclusion, these preclinical results, along with early promising clinical activity, suggest that CC-115 may be developed further for treatment of CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia : results of the first randomized phase III trial
- Author
-
Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Susan O'Brien, Paolo Ghia, Peter Hillmen, Kara Higgins, Richard R. Furman, Tadeusz Robak, Wojciech Jurczak, José A. García-Marco, Arnon P. Kater, Priti Patel, Stephan Stilgenbauer, Mustafa Nuri Yenerel, John C. Byrd, Asher Chanan-Khan, Neil E. Kay, Javier Pinilla-Ibarz, Árpád Illés, Anthony R. Mato, John F. Seymour, Sophia Sohoni, Stéphane Leprêtre, Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech, AII - Cancer immunology, Experimental Immunology, Clinical Haematology, and CCA - Cancer Treatment and Quality of Life
- Subjects
Adult ,Male ,Continuous therapy ,Oncology ,Cancer Research ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Prospective Studies ,Aged ,Aged, 80 and over ,business.industry ,Adenine ,Editorials ,Middle Aged ,Prognosis ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Rate ,Tolerability ,chemistry ,Pyrazines ,030220 oncology & carcinogenesis ,Ibrutinib ,Benzamides ,Acalabrutinib ,Female ,business ,Previously treated ,Tyrosine kinase ,Follow-Up Studies ,030215 immunology - Abstract
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL). METHODS Patients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib 100 mg twice daily or ibrutinib 420 mg once daily until progression or unacceptable toxicity. The primary end point was independent review committee–assessed noninferiority of progression-free survival (PFS). RESULTS Overall, 533 patients (acalabrutinib, n = 268; ibrutinib, n = 265) were randomly assigned. At the data cutoff, 124 (46.3%) acalabrutinib patients and 109 (41.1%) ibrutinib patients remained on treatment. After a median follow-up of 40.9 months, acalabrutinib was determined to be noninferior to ibrutinib with a median PFS of 38.4 months in both arms (95% CI acalabrutinib, 33.0 to 38.6 and ibrutinib, 33.0 to 41.6; hazard ratio: 1.00; 95% CI, 0.79 to 1.27). All-grade atrial fibrillation/atrial flutter incidence was significantly lower with acalabrutinib versus ibrutinib (9.4% v 16.0%; P = .02); among other selected secondary end points, grade 3 or higher infections (30.8% v 30.0%) and Richter transformations (3.8% v 4.9%) were comparable between groups and median overall survival was not reached in either arm (hazard ratio, 0.82; 95% CI, 0.59 to 1.15), with 63 (23.5%) deaths with acalabrutinib and 73 (27.5%) with ibrutinib. Treatment discontinuations because of adverse events occurred in 14.7% of acalabrutinib-treated patients and 21.3% of ibrutinib-treated patients. CONCLUSION In this first direct comparison of less versus more selective Bruton's tyrosine kinase inhibitors in CLL, acalabrutinib demonstrated noninferior PFS with fewer cardiovascular adverse events.
- Published
- 2021
42. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.
- Author
-
Pascutti, Maria Fernanda, Jak, Margot, Tromp, Jacqueline M., Derks, Ingrid A. M., Remmerswaal, Ester B. M., Thijssen, Rachel, van Attekum, Martijn H. A., van Bochove, Gregor G., Luijks, Dieuwertje M., Pals, Steven T., van Lier, Rene A. W., Kater, Arnon P., van Oers, Marinus H. J., and Eldering, Eric
- Subjects
- *
T cells , *CHRONIC lymphocytic leukemia , *CELL proliferation , *ANTIGENS , *B cell receptors - Abstract
Chronic lymphocytic leukemia (CLL) cells multiply in secondary lymphoid tissue, but the mechanisms leading to their proliferation are still uncertain. In addition to B-cell receptor (BCRHri9gered signals, other microenvironmental factors might well be involved. In proliferation centers, leukemic B cells are in close contact with CD4+CD40L+ T cells. Therefore, we here dissected the signals provided by autologous activated T cells (Tact) to CLL cells. Although the gene expression profile induced by Tact was highly similar to that induced by sole CD40 signaling, an obvious difference was that Tact induced proliferation of CLL cells. We determined that stimulation with only CD40L+IL-21 was sufficient to induce robust proliferation in CLL cells. We then defined an interleukin (IL)-21-induced gene signature in CLL, containing components of Janus kinase/signat transducer and activator of transcription and apoptosis pathways, and this signature could be detected in lymph node (LN) samples from patients. Finally, we could detect IL-21 RNA and protein in LN, and IL-21 production ex vivo by LN CD4+CXCR5+ follicular helper T celts. These results indicate that in addition to BCR signaling, activated T cells might contribute to CLL cell proliferation via CD40 and IL-21. Targeting these signaling pathways might offer new venues for treatment of CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
43. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.
- Author
-
de Weerdt, Iris, Eldering, Eric, van Oers, Marinus H., and Kater, Arnon P.
- Subjects
- *
CHRONIC lymphocytic leukemia treatment , *KINASE inhibitors , *CELLULAR signal transduction , *ANTINEOPLASTIC agents , *B cell receptors , *TUMOR necrosis factor receptors - Abstract
Abstract: Chronic lymphocytic leukemia (CLL) is still incurable, with considerable resistance to the standard therapy. CLL cells receive anti-apoptotic and pro-proliferation stimuli in lymph nodes and bone marrow, mainly through B cell receptor activation and TNF-receptor family ligation. In recent years, the focus for finding new drugs has shifted to blocking signals from the microenvironment. Novel therapeutical agents interfere with these microenvironmental interactions, and include inhibitors of kinases Syk, Btk and PI3Kδ. In this review we will focus on the microenvironmental interactions of CLL and the role of tyrosine kinases. Furthermore, early results from clinical trials with kinase inhibitors are discussed. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
44. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.
- Author
-
Guadagnoli, Marco, Kimberley, Fiona C., Phan, Uyen, Cameron, Katherine, Vink, Paul M., Rodermond, Hans, Eldering, Eric, Kater, Arnon P., van Eenennaam, Hans, and Medema, Jan Paul
- Subjects
- *
LIGANDS (Biochemistry) , *MONOCLONAL antibodies , *B cell lymphoma , *LYMPHOMAS , *CHRONIC lymphocytic leukemia - Abstract
APRIL (A proliferation-inducing ligand) is a TNF family member that binds two TNF receptor family members, TACI and BCMA. It shares these receptors with the closely related TNF family member, B-cell activating factor (BAFF). Contrary to BAFF, APRIL binds heparan sulfate proteoglycans (HSPGs), which regulates cross-linking of APRIL and efficient signaling. APRIL was originally identified as a growth promoter of solid tumors, and more recent evidence defines APRIL also as an important survival factor in several human B-cell malignancies, such as chronic lymphocytic leukemia (CLL). To target APRIL therapeutically, we developed two anti-human APRIL antibodies (hAPRIL.01A and hAPRIL.03A) that block APRIL binding to BCMA and TACI. Their antagonistic properties are unique when compared with a series of commercially available monoclonal anti-human APRIL antibodies as they prevent in vitro proliferation and IgA production of APRIL-reactive B cells. In addition, they effectively impair the CLL-like phenotype of aging APRIL transgenic mice and, more importantly, block APRIL binding to human B-cell lymphomas and prevent the survival effect induced by APRIL. We therefore conclude that these antibodies have potential for further development as therapeutics to target APRIL-dependent survival in B-cell malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.